메뉴 건너뛰기




Volumn 1012, Issue , 2004, Pages 306-325

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28

Author keywords

6 hydroxydopamine; Desferal; Iron; Iron chelation; Neuroprotection; Nigrostriatal dopamine neurons; Oxygen free radicals; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 HYDROXYINDOLEACETIC ACID; DEFEROXAMINE MESYLATE; DIHYDROXYPHENYLACETIC ACID; FERRITIN; GLUTATHIONE; GLUTATHIONE PEROXIDE; HOMOVANILLIC ACID; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; IRON CHELATING AGENT; NEUROTOXIN; NORADRENALIN; OXIDOPAMINE; RADICAL; SCAVENGER; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VK 28;

EID: 1842608744     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.025     Document Type: Article
Times cited : (210)

References (92)
  • 1
    • 3042530369 scopus 로고    scopus 로고
    • Iron in normal and pathological brain
    • Elsevier. Amsterdam/New York. In press
    • YOUDIM, M.B.H. & P. RIEDERER. 2004. Iron in normal and pathological brain. In Encyclopedia of Neuroscience. Elsevier. Amsterdam/New York. In press.
    • (2004) Encyclopedia of Neuroscience
    • Youdim, M.B.H.1    Riederer, P.2
  • 2
    • 0025963530 scopus 로고
    • Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
    • SOFIC, E. et al. 1991. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56: 978-982.
    • (1991) J. Neurochem. , vol.56 , pp. 978-982
    • Sofic, E.1
  • 3
    • 0024557734 scopus 로고
    • Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
    • RIEDERER, P. et al. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520.
    • (1989) J. Neurochem. , vol.52 , pp. 515-520
    • Riederer, P.1
  • 4
    • 84996111069 scopus 로고
    • Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    • YOUDIM, M.B.H., D. BEN-SHACHAR & P. RIEDERER. 1989. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126: 47-54.
    • (1989) Acta Neurol. Scand. Suppl. , vol.126 , pp. 47-54
    • Youdim, M.B.H.1    Ben-Shachar, D.2    Riederer, P.3
  • 5
    • 0036798434 scopus 로고    scopus 로고
    • Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
    • FAUCHEUX, B.A. et al. 2002. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83: 320-330.
    • (2002) J. Neurochem. , vol.83 , pp. 320-330
    • Faucheux, B.A.1
  • 6
    • 0024356620 scopus 로고
    • Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
    • DEXTER, D.T. et al. 1989. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52: 1830-1836.
    • (1989) J. Neurochem. , vol.52 , pp. 1830-1836
    • Dexter, D.T.1
  • 7
    • 0024585155 scopus 로고
    • Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
    • DEXTER, D.T. et al. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
    • (1989) J. Neurochem. , vol.52 , pp. 381-389
    • Dexter, D.T.1
  • 8
    • 0025606922 scopus 로고
    • Brain iron and ferritin in Parkinson's and Alzheimer's diseases
    • JELLINGER, K. et al. 1990. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Parkinson's Dis. Dementia Sect. 2: 327-340.
    • (1990) J. Neural Transm. Parkinson's Dis. Dementia Sect. , vol.2 , pp. 327-340
    • Jellinger, K.1
  • 9
    • 0026666528 scopus 로고
    • Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
    • JELLINGER, K. et al. 1992. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59: 1168-1171.
    • (1992) J. Neurochem. , vol.59 , pp. 1168-1171
    • Jellinger, K.1
  • 10
    • 0032975570 scopus 로고    scopus 로고
    • The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease
    • JELLINGER, K.A. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140.
    • (1999) Drugs Aging , vol.14 , pp. 115-140
    • Jellinger, K.A.1
  • 11
    • 0028000825 scopus 로고
    • Altered brain metabolism of iron as a cause of neurodegenerative diseases?
    • GERLACH, M. et al. 1994. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 793: 793-807.
    • (1994) J. Neurochem. , vol.793 , pp. 793-807
    • Gerlach, M.1
  • 12
    • 0034796353 scopus 로고    scopus 로고
    • Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment
    • HALLIWELL, B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716.
    • (2001) Drugs Aging , vol.18 , pp. 685-716
    • Halliwell, B.1
  • 13
    • 0026034279 scopus 로고
    • Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis
    • HIRSCH, E.C. et al. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451.
    • (1991) J. Neurochem. , vol.56 , pp. 446-451
    • Hirsch, E.C.1
  • 14
    • 0026662141 scopus 로고
    • Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    • KASTNER, A. et al. 1992. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59: 1080-1089.
    • (1992) J. Neurochem. , vol.59 , pp. 1080-1089
    • Kastner, A.1
  • 15
    • 0035043251 scopus 로고    scopus 로고
    • Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP)
    • TAKANASHI, M. et al. 2001. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinson's Relat. Disord. 7: 311-314.
    • (2001) Parkinson's Relat. Disord. , vol.7 , pp. 311-314
    • Takanashi, M.1
  • 16
    • 0000594895 scopus 로고
    • Brain iron metabolism: Biochemical and behavioral aspects in relation to dopaminergic neurotransmission
    • Plenum. New York
    • YOUDIM, M.B.H. 1985. Brain iron metabolism: biochemical and behavioral aspects in relation to dopaminergic neurotransmission. In Handbook of Neurochemistry. Plenum. New York.
    • (1985) Handbook of Neurochemistry
    • Youdim, M.B.H.1
  • 17
    • 0026337175 scopus 로고
    • Oxidative stress as a cause of Parkinson's disease
    • JENNER, P. 1991. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136: 6-15.
    • (1991) Acta Neurol. Scand. Suppl. , vol.136 , pp. 6-15
    • Jenner, P.1
  • 18
    • 0029751104 scopus 로고    scopus 로고
    • Oxidative stress and the pathogenesis of Parkinson's disease
    • JENNER, P. & C.W. OLANOW. 1996. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-S170.
    • (1996) Neurology , vol.47
    • Jenner, P.1    Olanow, C.W.2
  • 19
    • 0034079858 scopus 로고    scopus 로고
    • Oxidative stress, mitochondrial respiration, and Parkinson's disease
    • COHEN, G. 2000. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N.Y. Acad. Sci. 899: 112-120.
    • (2000) Ann. N.Y. Acad. Sci. , vol.899 , pp. 112-120
    • Cohen, G.1
  • 20
    • 0026733994 scopus 로고
    • MR1, brain iron, and experimental Parkinson's disease
    • HALL, S., J.N. RUTLEDGE & T. SCHALLERT. 1992. MR1, brain iron, and experimental Parkinson's disease. J. Neurol. Sci. 113: 198-208.
    • (1992) J. Neurol. Sci. , vol.113 , pp. 198-208
    • Hall, S.1    Rutledge, J.N.2    Schallert, T.3
  • 21
    • 0027991538 scopus 로고
    • Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study
    • OESTREICHER, E. et al. 1994. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660: 8-18.
    • (1994) Brain Res. , vol.660 , pp. 8-18
    • Oestreicher, E.1
  • 22
    • 0028045734 scopus 로고
    • Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis
    • TEMLETT, J.A. et al. 1994. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62: 134-146.
    • (1994) J. Neurochem. , vol.62 , pp. 134-146
    • Temlett, J.A.1
  • 23
    • 0028266425 scopus 로고
    • Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
    • MOCHIZUKI, H. et al. 1994. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168: 251-253.
    • (1994) Neurosci. Lett. , vol.168 , pp. 251-253
    • Mochizuki, H.1
  • 24
    • 0029662001 scopus 로고    scopus 로고
    • An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
    • GOTO, K. et al. 1996. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res. 724: 125-128.
    • (1996) Brain Res. , vol.724 , pp. 125-128
    • Goto, K.1
  • 25
    • 3042530369 scopus 로고    scopus 로고
    • Iron in the brain, normal and pathological
    • Elsevier. Amsterdam/New York
    • YOUDIM, M.B.H. & P. RIEDERER. 2002. Iron in the brain, normal and pathological. In Encyclopedia of Neuroscience. Elsevier. Amsterdam/New York.
    • (2002) Encyclopedia of Neuroscience
    • Youdim, M.B.H.1    Riederer, P.2
  • 26
    • 0036710567 scopus 로고    scopus 로고
    • Glutathione, iron, and Parkinson's disease
    • BHARATH, S. et al. 2002. Glutathione, iron, and Parkinson's disease. Biochem. Pharmacol. 64: 1037-1048.
    • (2002) Biochem. Pharmacol. , vol.64 , pp. 1037-1048
    • Bharath, S.1
  • 27
    • 0024805708 scopus 로고
    • Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain
    • PERUMAL, A.S. et al. 1989. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res. 504: 139-141.
    • (1989) Brain Res. , vol.504 , pp. 139-141
    • Perumal, A.S.1
  • 28
    • 0028916715 scopus 로고
    • Free radical-generated neurotoxicity of 6-hydroxydopamine
    • KUMAR, R., A.K. AGARWAL & P.K. SETH. 1995. Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64: 1703-1707.
    • (1995) J. Neurochem. , vol.64 , pp. 1703-1707
    • Kumar, R.1    Agarwal, A.K.2    Seth, P.K.3
  • 29
    • 0022650447 scopus 로고
    • Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment
    • YONG, V.W., T.L. PERRY & A.A. KRISMAN. 1986. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63: 56-60.
    • (1986) Neurosci. Lett. , vol.63 , pp. 56-60
    • Yong, V.W.1    Perry, T.L.2    Krisman, A.A.3
  • 30
    • 0035085603 scopus 로고    scopus 로고
    • Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
    • GRUNBLATT, E. et al. 2001. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77: 146-156.
    • (2001) J. Neurochem. , vol.77 , pp. 146-156
    • Grunblatt, E.1
  • 31
    • 0034941949 scopus 로고    scopus 로고
    • Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray
    • GRUNBLATT, E. et al. 2001. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78: 1-12.
    • (2001) J. Neurochem. , vol.78 , pp. 1-12
    • Grunblatt, E.1
  • 32
    • 0024368622 scopus 로고
    • 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
    • MONTEIRO, H.P. & C.C. WINTERBOURN. 1989. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38: 4177-4182.
    • (1989) Biochem. Pharmacol. , vol.38 , pp. 4177-4182
    • Monteiro, H.P.1    Winterbourn, C.C.2
  • 33
    • 0025677734 scopus 로고
    • Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions
    • LODE, H.N. et al. 1990. Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radical Res. Commun. 11: 153-158.
    • (1990) Free Radical Res. Commun. , vol.11 , pp. 153-158
    • Lode, H.N.1
  • 34
    • 0030598917 scopus 로고    scopus 로고
    • Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease
    • LINERT, W. et al. 1996. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316: 160-168.
    • (1996) Biochim. Biophys. Acta , vol.1316 , pp. 160-168
    • Linert, W.1
  • 35
    • 0034724378 scopus 로고    scopus 로고
    • Interaction between 6-hydroxydopamine and transferrin: "let my iron go"
    • BORISENKO, G.G. et al. 2000. Interaction between 6-hydroxydopamine and transferrin: "let my iron go". Biochemistry 39: 3392-3400.
    • (2000) Biochemistry , vol.39 , pp. 3392-3400
    • Borisenko, G.G.1
  • 36
    • 0030790785 scopus 로고    scopus 로고
    • Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
    • PEZZELLA, A. et al. 1997. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40: 2211-2216.
    • (1997) J. Med. Chem. , vol.40 , pp. 2211-2216
    • Pezzella, A.1
  • 37
    • 0001204988 scopus 로고    scopus 로고
    • Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: Potential implications to Parkinson's disease
    • HAN, J. et al. 1999. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem. 73: 1683-1695.
    • (1999) J. Neurochem. , vol.73 , pp. 1683-1695
    • Han, J.1
  • 38
    • 0024500857 scopus 로고
    • Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence
    • CADET, J.L. et al. 1989. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476: 10-15.
    • (1989) Brain Res. , vol.476 , pp. 10-15
    • Cadet, J.L.1
  • 39
    • 0030606143 scopus 로고    scopus 로고
    • Melatonin is protective against MPTP-induced striatal and hippocampal lesions
    • ACUNA-CASTROVIEJO, D. et al. 1997. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60: L23-L29.
    • (1997) Life Sci. , vol.60
    • Acuna-Castroviejo, D.1
  • 40
    • 0030592141 scopus 로고    scopus 로고
    • Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
    • GASSEN, M. et al. 1996. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308: 219-225.
    • (1996) Eur. J. Pharmacol. , vol.308 , pp. 219-225
    • Gassen, M.1
  • 42
    • 0030864433 scopus 로고    scopus 로고
    • Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
    • Budapest
    • LAN, J. & D.H. JIANG. 1997. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. (Budapest) 104: 469-481.
    • (1997) J. Neural Transm. , vol.104 , pp. 469-481
    • Lan, J.1    Jiang, D.H.2
  • 43
    • 0030666415 scopus 로고    scopus 로고
    • Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease
    • LAN, J. & D.H. JIANG. 1997. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104: 649-660.
    • (1997) J. Neural Transm. , vol.104 , pp. 649-660
    • Lan, J.1    Jiang, D.H.2
  • 44
    • 0034851553 scopus 로고    scopus 로고
    • Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration
    • LEVITES, Y. et al. 2001. Green tea polyphenol (-)-epigallocatechin-3- gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78: 1073-1082.
    • (2001) J. Neurochem. , vol.78 , pp. 1073-1082
    • Levites, Y.1
  • 45
    • 0033669158 scopus 로고    scopus 로고
    • The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease
    • MOUSSAOUI, S. et al. 2000. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166: 235-245.
    • (2000) Exp. Neurol. , vol.166 , pp. 235-245
    • Moussaoui, S.1
  • 46
    • 0035895844 scopus 로고    scopus 로고
    • Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: Behavioral and histochemical evidence
    • ROGHANI, M. & G. BEHZADI. 2001. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 892: 211-217.
    • (2001) Brain Res. , vol.892 , pp. 211-217
    • Roghani, M.1    Behzadi, G.2
  • 47
    • 0025980955 scopus 로고
    • The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine- induced degeneration of nigrostriatal dopamine neurons
    • BEN-SHACHAR, D. et al. 1991. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56: 1441-1444.
    • (1991) J. Neurochem. , vol.56 , pp. 1441-1444
    • Ben-Shachar, D.1
  • 48
    • 0242684415 scopus 로고    scopus 로고
    • Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease
    • KAUR, D. et al. 2003. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909.
    • (2003) Neuron , vol.37 , pp. 899-909
    • Kaur, D.1
  • 49
    • 0025824668 scopus 로고
    • Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats
    • BEN-SHACHAR, D. & M.B. YOUDIM. 1991. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57: 2133-2135.
    • (1991) J. Neurochem. , vol.57 , pp. 2133-2135
    • Ben-Shachar, D.1    Youdim, M.B.2
  • 50
    • 0014376793 scopus 로고
    • 6-Hydroxy-dopamine induced degeneration of central monoamine neurons
    • UNGERSTEDT, U. 1968. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5: 107-110.
    • (1968) Eur. J. Pharmacol. , vol.5 , pp. 107-110
    • Ungerstedt, U.1
  • 51
    • 0014731101 scopus 로고
    • Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain
    • URETSKY, N.J. & L.L. IVERSEN. 1970. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J. Neurochem. 17: 269-278.
    • (1970) J. Neurochem. , vol.17 , pp. 269-278
    • Uretsky, N.J.1    Iversen, L.L.2
  • 52
    • 0027497409 scopus 로고
    • Parkinson's disease and increased iron in substantia nigra zona compacta
    • YOUDIM, M.B.H., D. BEN-SHACHAR & P. RIEDERER. 1993. Parkinson's disease and increased iron in substantia nigra zona compacta. Mov. Disord. 8: 1-12.
    • (1993) Mov. Disord. , vol.8 , pp. 1-12
    • Youdim, M.B.H.1    Ben-Shachar, D.2    Riederer, P.3
  • 53
    • 0032765888 scopus 로고    scopus 로고
    • Iron accumulation in the substantia nigra in rats visualized by ultrasound
    • BERG, D. et al. 1999. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25: 901-904.
    • (1999) Ultrasound Med. Biol. , vol.25 , pp. 901-904
    • Berg, D.1
  • 54
    • 0034776216 scopus 로고    scopus 로고
    • Brain iron pathways and their relevance to Parkinson's disease
    • BERG, D. et al. 2001. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79: 225-236.
    • (2001) J. Neurochem. , vol.79 , pp. 225-236
    • Berg, D.1
  • 55
    • 0027497409 scopus 로고
    • The possible role of iron in the etiopathology of Parkinson's disease
    • YOUDIM, M.B., D. BEN-SHACHAR & P. RIEDERER. 1993. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8: 1-12.
    • (1993) Mov. Disord. , vol.8 , pp. 1-12
    • Youdim, M.B.1    Ben-Shachar, D.2    Riederer, P.3
  • 56
    • 0033373789 scopus 로고    scopus 로고
    • The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration: Prospects for neuroprotection in Parkinson's disease with iron chelators
    • YOUDIM, M.B.H., E. GRUNBLATT & S. MANDEL. 1999. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration: prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. N.Y. Acad. Sci. 890: 7-25.
    • (1999) Ann. N.Y. Acad. Sci. , vol.890 , pp. 7-25
    • Youdim, M.B.H.1    Grunblatt, E.2    Mandel, S.3
  • 57
    • 0035474950 scopus 로고    scopus 로고
    • Recent advances in disorders of iron metabolism: Mutations, mechanisms, and modifiers
    • ROY, C.N. & N.C. ANDREWS. 2001. Recent advances in disorders of iron metabolism: mutations, mechanisms, and modifiers. Hum. Mol. Genet. 10: 2181-2186.
    • (2001) Hum. Mol. Genet. , vol.10 , pp. 2181-2186
    • Roy, C.N.1    Andrews, N.C.2
  • 58
    • 0035095564 scopus 로고    scopus 로고
    • Brain iron transport and neurodegeneration
    • QIAN, Z.M. & X. SHEN. 2001. Brain iron transport and neurodegeneration. Trends Mol. Med. 7: 103-108.
    • (2001) Trends Mol. Med. , vol.7 , pp. 103-108
    • Qian, Z.M.1    Shen, X.2
  • 59
    • 0030891276 scopus 로고    scopus 로고
    • The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders
    • GASSEN, M. & M.B. YOUDIM. 1997. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80: 159-166.
    • (1997) Pharmacol. Toxicol. , vol.80 , pp. 159-166
    • Gassen, M.1    Youdim, M.B.2
  • 60
    • 0343550312 scopus 로고    scopus 로고
    • Apomorphine protects against MPTP-induced neurotoxicity in mice
    • GRUNBLATT, E. et al. 1999. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14: 612-618.
    • (1999) Mov. Disord. , vol.14 , pp. 612-618
    • Grunblatt, E.1
  • 61
    • 0025224512 scopus 로고
    • Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions
    • SALAMONE, J.D., M.J. ZIGMOND & E.M. STRICKER. 1990. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience 39: 17-24.
    • (1990) Neuroscience , vol.39 , pp. 17-24
    • Salamone, J.D.1    Zigmond, M.J.2    Stricker, E.M.3
  • 62
    • 0018858892 scopus 로고
    • Supersensitivity after intraventricular 6-hydroxydopamine: Relation to dopamine depletion
    • ZIGMOND, M.J. & E.M. STRICKER. 1980. Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia 36: 436-438.
    • (1980) Experientia , vol.36 , pp. 436-438
    • Zigmond, M.J.1    Stricker, E.M.2
  • 63
    • 0018854896 scopus 로고
    • Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine
    • ACHESON, A.L., M.J. ZIGMOND & E.M. STRICKER. 1980. Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine. Science 207: 537-540.
    • (1980) Science , vol.207 , pp. 537-540
    • Acheson, A.L.1    Zigmond, M.J.2    Stricker, E.M.3
  • 64
    • 0038322479 scopus 로고    scopus 로고
    • cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells
    • WEINREB, O., S. MANDEL & M.B.H. YOUDIM. 2003. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. 17: 935-937.
    • (2003) FASEB J. , vol.17 , pp. 935-937
    • Weinreb, O.1    Mandel, S.2    Youdim, M.B.H.3
  • 65
    • 0027351360 scopus 로고
    • The neurotoxicity of iron and nitric oxide: Relevance to the etiology of Parkinson's disease
    • YOUDIM, M.B.H. et al. 1993. The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease. Adv. Neurol. 60: 259-266.
    • (1993) Adv. Neurol. , vol.60 , pp. 259-266
    • Youdim, M.B.H.1
  • 66
    • 0025640845 scopus 로고    scopus 로고
    • Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
    • SCHAPIRA, A.H. et al. 2003. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55: 2142-2145.
    • (2003) J. Neurochem. , vol.55 , pp. 2142-2145
    • Schapira, A.H.1
  • 67
    • 0035233083 scopus 로고    scopus 로고
    • Causes of neuronal death in Parkinson's disease
    • SCHAPIRA, A.H. 2001. Causes of neuronal death in Parkinson's disease. Adv. Neurol. 86: 155-162.
    • (2001) Adv. Neurol. , vol.86 , pp. 155-162
    • Schapira, A.H.1
  • 68
    • 0029969350 scopus 로고    scopus 로고
    • Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine
    • GLINKA, Y., K.F. TIPTON & M.B. YOUDIM. 1996. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 66: 2004-2010.
    • (1996) J. Neurochem. , vol.66 , pp. 2004-2010
    • Glinka, Y.1    Tipton, K.F.2    Youdim, M.B.3
  • 69
    • 0032511134 scopus 로고    scopus 로고
    • Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine
    • GLINKA, Y., K.F. TIPTON & M.B.H. YOUDIM. 1998. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. 351: 121-129.
    • (1998) Eur. J. Pharmacol. , vol.351 , pp. 121-129
    • Glinka, Y.1    Tipton, K.F.2    Youdim, M.B.H.3
  • 70
    • 0028918841 scopus 로고
    • Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
    • GLINKA, Y.Y. & M.B. YOUDIM. 1995. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292: 329-332.
    • (1995) Eur. J. Pharmacol. , vol.292 , pp. 329-332
    • Glinka, Y.Y.1    Youdim, M.B.2
  • 71
    • 0023179660 scopus 로고
    • Inhibition of NADH oxidation by pyridine derivatives
    • RAMSAY, R.R. et al. 1987. Inhibition of NADH oxidation by pyridine derivatives. Biochem. Biophys. Res. Commun. 1: 53-60.
    • (1987) Biochem. Biophys. Res. Commun. , vol.1 , pp. 53-60
    • Ramsay, R.R.1
  • 72
    • 0031589740 scopus 로고    scopus 로고
    • Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors
    • SEATON, T.A., J.M. COOPER & A.H. SCHAPIRA. 1997. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777: 110-118.
    • (1997) Brain Res. , vol.777 , pp. 110-118
    • Seaton, T.A.1    Cooper, J.M.2    Schapira, A.H.3
  • 73
    • 0037378023 scopus 로고    scopus 로고
    • Neuroinflammatory processes in Parkinson's disease
    • HUNOT, S. & E.C. HIRSCH. 2003. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. Suppl. 3: S49-S58.
    • (2003) Ann. Neurol. Suppl. , vol.3
    • Hunot, S.1    Hirsch, E.C.2
  • 74
    • 0030842085 scopus 로고    scopus 로고
    • Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease
    • HUNOT, S. et al. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94: 7531-7536.
    • (1997) Proc. Natl. Acad. Sci. USA , vol.94 , pp. 7531-7536
    • Hunot, S.1
  • 75
    • 1642555537 scopus 로고    scopus 로고
    • Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases
    • SHOHAM, S. & M.B.H. YOUDIM. 2000. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell. Mol. Biol. 46: 743-760.
    • (2000) Cell. Mol. Biol. , vol.46 , pp. 743-760
    • Shoham, S.1    Youdim, M.B.H.2
  • 76
    • 0036145435 scopus 로고    scopus 로고
    • Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures
    • LEVITES, Y. et al. 2002. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63: 21-29.
    • (2002) Biochem. Pharmacol. , vol.63 , pp. 21-29
    • Levites, Y.1
  • 77
    • 0030858597 scopus 로고    scopus 로고
    • Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages
    • LIN, M. et al. 1997. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am. J. Physiol. 272: G1355-G1364.
    • (1997) Am. J. Physiol. , vol.272
    • Lin, M.1
  • 78
    • 1542537139 scopus 로고    scopus 로고
    • Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats
    • In press
    • BEN-SHACHAR, D. et al. 2003. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. J. Neurochem. In press.
    • (2003) J. Neurochem.
    • Ben-Shachar, D.1
  • 79
    • 0037097199 scopus 로고    scopus 로고
    • Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain
    • SIDDAPPA, A.J. et al. 2002. Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain. J. Neurosci. Res. 68: 761-775.
    • (2002) J. Neurosci. Res. , vol.68 , pp. 761-775
    • Siddappa, A.J.1
  • 80
    • 0033826764 scopus 로고    scopus 로고
    • Iron regulatory proteins and the molecular control of mammalian iron metabolism
    • EISENSTEIN, R.S. 2000. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20: 627-662.
    • (2000) Annu. Rev. Nutr. , vol.20 , pp. 627-662
    • Eisenstein, R.S.1
  • 81
    • 0032746973 scopus 로고    scopus 로고
    • Control of transferrin receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2
    • KIM, S. & P. PONKA. 1999. Control of transferrin receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2. J. Biol. Chem. 274: 33035-33042.
    • (1999) J. Biol. Chem. , vol.274 , pp. 33035-33042
    • Kim, S.1    Ponka, P.2
  • 82
    • 0035138456 scopus 로고    scopus 로고
    • Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice
    • LAVAUTE, T. et al. 2001. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214.
    • (2001) Nat. Genet. , vol.27 , pp. 209-214
    • LaVaute, T.1
  • 83
    • 0024434025 scopus 로고
    • The putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior
    • discussion, pp. 615-617
    • YOUDIM, M.B.H., D. BEN-SHACHAR & S. YEHUDA. 1989. The putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am. J. Clin. Nutr. 50: 607-615 (discussion, pp. 615-617).
    • (1989) Am. J. Clin. Nutr. , vol.50 , pp. 607-615
    • Youdim, M.B.H.1    Ben-Shachar, D.2    Yehuda, S.3
  • 84
    • 0141940629 scopus 로고    scopus 로고
    • What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease
    • (a) YOUDIM, M.B.H. 2003. What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease. J. Neural Transm. Suppl. 65: 73-88;
    • (2003) J. Neural Transm. Suppl. , vol.65 , pp. 73-88
    • Youdim, M.B.H.1
  • 85
    • 1842621154 scopus 로고    scopus 로고
    • Iron and alpha-synuclein in the substantia nigra of MPTP treated mice: Effects of neuroprotective drugs R-apomorphine and green tea polyphenol, epigallocatechin-3-gallate
    • In press
    • (b) MANDEL, S., G. MAOR & M.B.H. YOUDIM. 2004. Iron and alpha-synuclein in the substantia nigra of MPTP treated mice: effects of neuroprotective drugs R-apomorphine and green tea polyphenol, epigallocatechin-3-gallate. J. Mol. Neurosci. In press.
    • (2004) J. Mol. Neurosci.
    • Mandel, S.1    Maor, G.2    Youdim, M.B.H.3
  • 86
    • 0037013194 scopus 로고    scopus 로고
    • Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein
    • GOLTS, N. et al. 2002. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277: 16116-16123.
    • (2002) J. Biol. Chem. , vol.277 , pp. 16116-16123
    • Golts, N.1
  • 87
    • 0034663039 scopus 로고    scopus 로고
    • The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity
    • OSTREROVA-GOLTS, N. et al. 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20: 6048-6054.
    • (2000) J. Neurosci. , vol.20 , pp. 6048-6054
    • Ostrerova-Golts, N.1
  • 88
    • 0026475580 scopus 로고
    • Iron accumulation in the rat basal ganglia after excitatory amino acid injections - Dissociation from neuronal loss
    • SHOHAM, S., E. WERTMAN & R.P. EBSTEIN. 1992. Iron accumulation in the rat basal ganglia after excitatory amino acid injections - dissociation from neuronal loss. Exp. Neurol. 118: 227-241.
    • (1992) Exp. Neurol. , vol.118 , pp. 227-241
    • Shoham, S.1    Wertman, E.2    Ebstein, R.P.3
  • 89
    • 0002404319 scopus 로고    scopus 로고
    • Brain iron: Function and dysfunction in relation to cognitive processes
    • Libbey. London
    • SHOHAM, S. et al. 1996. Brain iron: function and dysfunction in relation to cognitive processes. In Iron Nutrition in Health and Disease. Libbey. London.
    • (1996) Iron Nutrition in Health and Disease
    • Shoham, S.1
  • 90
    • 0345714885 scopus 로고    scopus 로고
    • Iron misregulation in the brain: A primary cause of neurodegenerative disorders
    • KE, Y. & Z. MING QIAN. 2003. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2: 246-253.
    • (2003) Lancet Neurol. , vol.2 , pp. 246-253
    • Ke, Y.1    Ming Qian, Z.2
  • 91
    • 1842516707 scopus 로고    scopus 로고
    • Effect of dietary iron on motor behaviour and neuronal death in an experimental model of parkinsonism
    • In press
    • LEVENSON, C.W. et al. 2003. Effect of dietary iron on motor behaviour and neuronal death in an experimental model of parkinsonism. J. Am. Aging Assoc. In press.
    • (2003) J. Am. Aging Assoc.
    • Levenson, C.W.1
  • 92
    • 0036113819 scopus 로고    scopus 로고
    • The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications
    • PERRY, G. et al. 2002. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16: 339-352.
    • (2002) CNS Drugs , vol.16 , pp. 339-352
    • Perry, G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.